Valneva takes a nosedive before steadying: what’s really going on with the stock and the VLA2001 vaccine?
If you've been following this French biotech for the past decade, you know that a rollercoaster ride is par for the course. But what happened to Valneva this week would leave even seasoned investors wincing. The stock brutally broke below €4.35, flirting with €3.89 before showing some signs of a rebound. This kind of turbulence always creates a frenzy among retail investors. So, what’s behind this latest about-turn?
Solid financials, but a fickle market mood
You have to put things in context. According to the financial results released a few days ago, the fundamentals are sound. Revenues are there, cash flow is holding up, and vaccine candidate development is progressing. So why the drop? Because in the stock market, especially for a company of this size, the devil is in the expectations. The market was probably hoping for a more aggressive outlook, or more headline-grabbing announcements regarding the progress of its high-profile Lyme disease vaccine.
But this is science, not magic. Thomas Lingelbach, the CEO, reiterates this every time he speaks: developing preventative vaccines against infectious diseases isn’t something that happens overnight. VLA15 (the name of their Lyme disease candidate) is probably the most closely watched programme in the industry, because if it succeeds, it would be the first true "goldmine" in modern history against this disease. But until the final green light comes, the share price remains under pressure.
VLA2001, the COVID vaccine that changed the game... and expectations
Let's not forget where they came from. With VLA2001, Valneva proved they could compete with the big players. This inactivated virus vaccine, used notably within the framework of strict protocols, was a much-needed lifeline. Incidentally, for those following regulatory aspects, the Generic Protocol for ECDC Studies of COVID-19 Vaccine Effectiveness Against Confirmed SARS-CoV-2 Using Healthcare Worker Cohorts: Version 3.0 remains a key reference for evaluating real-world effectiveness.
But today, the market has a short memory. The COVID era is behind us, and investors don't want to hear about legacy vaccines. They want something new, something disruptive. And right now, Valneva finds itself in a bit of a lull, caught between the end of the COVID hype and its Lyme pipeline still maturing. This is often the phase where stocks suffer the most, because traders hate uncertainty. They much prefer blockbuster quarterly announcements to quiet waiting periods.
Reasons for optimism (or caution) going forward
So, what should you do if you hold Valneva in your portfolio or are eyeing the stock with interest? Here are a few points worth considering:
- Cash and visibility: The company has secured funding and partnerships. It’s not going to vanish overnight. The financial results confirm this: there’s enough there to see it through to the next major milestones.
- The Lyme timeline: VLA15 is the primary catalyst. The next data readouts, if positive, could literally send the stock soaring. It’s a binary outcome, but with enormous potential.
- Thomas Lingelbach’s experience: He’s no novice. He’s navigated far worse storms than this minor market chill. His strategy, focused on developing preventative vaccines, remains consistent.
On the stock market, emotions are often amplified with this type of stock. The drop below €4.35 triggered stop-losses, automatic selling, which mechanically amplified the move. It’s textbook. What’s more interesting is whether the stock manages to stabilise above this psychological threshold in the coming sessions. If it does, the technical rebound could be just as sharp as the fall.
Let’s be honest, betting on Valneva today is betting on the future of biotech, with all the risks and rewards that entails. But those who held on during the uncertain phases around VLA2001 will remember: when the science delivers, the market always catches up eventually.